학술논문
Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study
Document Type
article
Author
Sylvain Lamure; Rémy Duléry; Roberta Di Blasi; Adrien Chauchet; Cécile Laureana; Bénédicte Deau-Fischer; Bernard Drenou; Carole Soussain; Cédric Rossi; Nicolas Noël; Sylvain Choquet; Serge Bologna; Bertrand Joly; Milena Kohn; Sandra Malak; Guillemette Fouquet; Etienne Daguindau; Sophie Bernard; Catherine Thiéblemont; Guillaume Cartron; Karine Lacombe; Caroline Besson
Source
EClinicalMedicine, Vol 27, Iss , Pp 100549- (2020)
Subject
Language
English
ISSN
2589-5370
Abstract
Background: Patients with lymphoma are immunocompromised because of the disease per se and its treatments. We aimed to describe the characteristics of patients with lymphoma hospitalized for Coronavirus Disease 2019 (Covid-19) and to analyze pre-Covid-19 determinants of mortality. Methods: This retrospective multicentric cohort study used the Programme de Médicalisation des Systèmes d'Information database to identify all adult patients with lymphoma, hospitalized for Covid-19 in March and April 2020, in 12 hospitals of three French regions with pandemic outbreaks. The characteristics of lymphoma and Covid-19 were collected from medical charts. Findings: Eighty-nine patients were included. The median age was 67 years (range, 19–92), 66% were male and 72% had a comorbidity. Most patients had B-cell non-Hodgkin lymphoma (86%) and had received a lymphoma treatment within one year (70%). With a median follow-up of 33 days from admission, 30-day overall survival was 71%, (95% confidence interval, 62–81%). In multivariable analysis, having an age ≥ 70 years (hazard ratio 2·87, 1·20–6·85, p = 0·02) and relapsed/refractory lymphoma (hazard ratio 2·54, 1·14–5·66, p = 0·02) were associated with mortality. Recent bendamustine treatment (n = 9) was also pejorative (hazard ratio 3·20, 1·33–7·72, p = 0·01), but was strongly associated with relapsed/refractory lymphoma. Remarkably, 30-day overall survival for patients